Page 20 - City of Hope HHI 2024 Spirit of Life Journal

Fund a Need
Every guest will have the opportunity to support the Leukemia Research Accelerator Fund during the Spirit of Life® dinner program.
Leukemia is one of the deadliest cancers
in existence. Leukemia is a complex blood cancer that originates in the bone marrow and swiftly multiplies, gradually overwhelming
the immune system’s ability to fight infection. One of its most common forms, acute myeloid leukemia (AML), has a five-year survival rate of just under 30%.
Under the leadership of Guido Marcucci, M.D., the 14 world-class scientists and physicians at the Gehr Family Center for Leukemia Research (working within City of Hope’s Hematologic Malignancies Research Institute) focus exclusively on research and care for patients with leukemia.
WHAT DO AML ACCELERATOR FUNDS DO?
Supporting Accelerator funds for AML is a powerful way to help accelerate the work of physician-scientists at City of Hope. At this critical moment of discovery and innovation, philanthropic investment can help speed
the completion of groundbreaking research, expedite clinical trials and the development of new therapies to save the lives of thousands of patients worldwide.
AML RESEARCH ACCELERATOR FUND
City of Hope research scientists are charting a new course in the fight against AML, one of this cancer’s most common and deadly
forms. MiRisten, a new medication created at City of Hope, carefully alters the bone marrow environment to kill the leukemia stem cells that produce AML. Initial research shows that miRisten is highly effective against very tough cases of AML, and our leukemia researchers are working to swiftly advance this promising drug into in-human clinical trials.
20 | CITY OF HOPE